CA2687786A1 - Combination of chk and parp inhibitors for the treatment of cancers - Google Patents

Combination of chk and parp inhibitors for the treatment of cancers Download PDF

Info

Publication number
CA2687786A1
CA2687786A1 CA2687786A CA2687786A CA2687786A1 CA 2687786 A1 CA2687786 A1 CA 2687786A1 CA 2687786 A CA2687786 A CA 2687786A CA 2687786 A CA2687786 A CA 2687786A CA 2687786 A1 CA2687786 A1 CA 2687786A1
Authority
CA
Canada
Prior art keywords
6alkyl
optionally substituted
cancer
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2687786A
Other languages
English (en)
French (fr)
Inventor
Mark James O'connor
Graeme Cameron Murray Smith
Sonya Zabludoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2687786A1 publication Critical patent/CA2687786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2687786A 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers Abandoned CA2687786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
US60/940,203 2007-05-25
PCT/GB2008/050372 WO2008146035A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Publications (1)

Publication Number Publication Date
CA2687786A1 true CA2687786A1 (en) 2008-12-04

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2687786A Abandoned CA2687786A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Country Status (11)

Country Link
US (1) US20100249112A1 (enExample)
EP (1) EP2167086A1 (enExample)
JP (1) JP2010527981A (enExample)
KR (1) KR20100020981A (enExample)
CN (1) CN101743003A (enExample)
AU (1) AU2008256562A1 (enExample)
BR (1) BRPI0811059A2 (enExample)
CA (1) CA2687786A1 (enExample)
MX (1) MX2009012705A (enExample)
RU (1) RU2009147819A (enExample)
WO (1) WO2008146035A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ(adpリボース)ポリメラーゼ−1阻害剤としての、置換4−(4−フルオロ−3−(ピペラジン−1−カルボニル)ベンジル)フタラジン−1(2h)−オン誘導体
US20140044802A1 (en) * 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR102645511B1 (ko) * 2017-04-10 2024-03-08 시에라 온코로지 엘엘씨 종양 성장을 저해하는 CHK1(SRA737)/PARPi 조합 방법
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CN111936143A (zh) 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Chk1抑制劑之合成方法
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004220321B2 (en) * 2003-03-12 2010-02-25 Kudos Pharmaceuticals Ltd Phthalazinone derivatives
TWI338000B (en) * 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
WO2005066163A2 (en) * 2004-01-05 2005-07-21 Astrazeneca Ab Thiophene derivatives as chk 1 inihibitors
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Also Published As

Publication number Publication date
KR20100020981A (ko) 2010-02-23
US20100249112A1 (en) 2010-09-30
CN101743003A (zh) 2010-06-16
WO2008146035A1 (en) 2008-12-04
BRPI0811059A2 (pt) 2017-05-09
MX2009012705A (es) 2009-12-08
RU2009147819A (ru) 2011-06-27
AU2008256562A1 (en) 2008-12-04
EP2167086A1 (en) 2010-03-31
JP2010527981A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
US20100249112A1 (en) Combination of chk and parp inhibitors for the treatment of cancers
AU2010364807B2 (en) Heterocyclic derivates, preparation processes and medical uses thereof
CA2517629C (en) Phthalazinone derivatives
ES2364140T3 (es) Derivados de ftalazinona.
CN102686591B (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
JP2009512671A (ja) 4−ヘテロアリールメチル置換されたフタラジノン誘導体
TW200900396A (en) Phthalazinone derivatives
AU2008313504A1 (en) Combination 059
KR20070057859A (ko) 4-헤테로아릴메틸 치환된 프탈라지논 유도체
CN102898377A (zh) 一类新型酞嗪酮衍生物及其用途
WO2022261220A1 (en) Proteolysis targeting chimeras and methods of use thereof
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
US20040127504A1 (en) Benzimidazoles that are useful in treating sexual dysfunction
AU2008299721A1 (en) Phthalazinone derivatives
CN115381832A (zh) 癌症的治疗
CN110272419A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN117384161A (zh) 靶向降解cdk蛋白的化合物及其应用
CN115836077B (zh) 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
EP3878841B1 (en) Indazole kinase inhibitor and use thereof
HK40083903A (en) Treatment of cancer
CN117777124A (zh) Parp选择性抑制剂
US20100240645A1 (en) Combination of checkponit kinase (chk) and telangiectasia mutated (atm) inhibitors for the treatment of cancer
HK40001545A (en) Treatment of cancer
HK40009984A (en) Erbb inhibitors and uses thereof
MX2008004913A (en) 4-heteroarymethyl substituted phthalazinone derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130523